FEATURES
Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.
 

 
By Dr. Dragan Cicic, Actinium Pharmaceuticals Inc.
Patients with blood cancers often face poor long-term survival outcomes, but a new treatment approach could offer more effective targeting of cancer cells as well as lower toxicity.
 
By Kelsey Kaustinen, DDNews Senior Editor
If all milestones are met, the agreement could be worth up to $817 million
 
By Kelsey Kaustinen, DDNews Senior Editor
The effectiveness of anthracyclines, a standard of cancer care, is marred by the associated heart damage they cause; a recent study, however, reports that wrapping the drugs in a fatty cover can minimize cardiotoxicity.
 
By Lloyd Dunlap, DDNews Managing Editor
Immunomedics Inc. has received notice from the U.S. Food and Drug Administration designating as a Fast Track development program the investigation of sacituzumab govitecan, the company's lead antibody-drug conjugate, for the treatment of patients with triple-negative breast cancer
 
By Kelsey Kaustinen, DDNews Senior Editor
When the STP axis is expressed, causing low REST protein levels, clinical outcomes in the lab are poor, while inhibition of the axis was found to increase REST levels, which impaired tumor formation and progression.
 
 
 

 
 
Clinical Genomics Center established by Lab21, ITOR
April 2012
SHARING OPTIONS:

CAMBRIDGE, U.K.—Lab21 recently launched a new Clinical Genomics Center at the Greenville Hospital System (GHS) Memorial Medical Campus in Greenville, S.C. Located in the GHS Institute for Translational Oncology Research (ITOR), the new center continues an ongoing collaboration to introduce complex biomarker analysis into routine cancer patient management. A strategic relationship with Life Technologies, whose Ion Torrent Personal Genome Machine will serve as the key launch platform technology, led to the establishment of the facility.  
 
"Bringing this leading-edge technology to the cancer clinic represents a significant breakthrough and the culmination of a seven-year journey," Dr. Joe Stephenson, medical director for ITOR, noted in a statement. "This genomics center is another major step towards fulfilling our vision to provide personalized cancer care—better enabling us to offer the right drug, at the right time, to the right patient."

Back
 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2015 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.